Malignant thymoma: Long-term outcomes with radiotherapy

Genomic Medicine, Biomarkers, and Health Sciences Pub Date : 2011-09-01 DOI:10.1016/j.gmbhs.2012.02.001

Ming-Yii Huang , Chih-Jen Huang , Jen-Yang Tang , Chun-Ming Huang , Sheau-Fang Yang , Shah-Hwa Chou

{"title":"Malignant thymoma: Long-term outcomes with radiotherapy","authors":"Ming-Yii Huang , Chih-Jen Huang , Jen-Yang Tang , Chun-Ming Huang , Sheau-Fang Yang , Shah-Hwa Chou","doi":"10.1016/j.gmbhs.2012.02.001","DOIUrl":null,"url":null,"abstract":"<div><p>We analyzed the clinical outcome of stage II to IV malignant thymoma. This study focused on the treatment of 60 cases that combined surgery (biopsy or resection) and radiation therapy (with or without chemotherapy). Univariate and multivariate analyses of prognostic factors predicting survival were carried out. There is a statistically significant relationship between the extent of surgery and the local control (19.4% of relapse after complete resection vs. 41.2% of relapse after partial resection or biopsy, <em>p</em>   =0.0001) and distant metastasis (<em>p</em>   <!-->Gy) for patients with malignant thymoma.</p></div>","PeriodicalId":100577,"journal":{"name":"Genomic Medicine, Biomarkers, and Health Sciences","volume":"3 3","pages":"Pages 111-118"},"PeriodicalIF":0.0000,"publicationDate":"2011-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gmbhs.2012.02.001","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genomic Medicine, Biomarkers, and Health Sciences","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2211425412000027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

We analyzed the clinical outcome of stage II to IV malignant thymoma. This study focused on the treatment of 60 cases that combined surgery (biopsy or resection) and radiation therapy (with or without chemotherapy). Univariate and multivariate analyses of prognostic factors predicting survival were carried out. There is a statistically significant relationship between the extent of surgery and the local control (19.4% of relapse after complete resection vs. 41.2% of relapse after partial resection or biopsy, p = 0.0001). Mediastinal radiation dose (≥50 Gy) had a significant effect in decreasing recurrence (p = 0.0001) and distant metastasis (p = 0.011). The rates of local recurrence (30%) and distant metastasis (25%) justify recommending a higher dose of mediastinal radiation (≥50 Gy) for patients with malignant thymoma.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

恶性胸腺瘤:放疗的长期结果

我们分析了II期至IV期恶性胸腺瘤的临床结果。本研究的重点是60例联合手术(活检或切除)和放射治疗(有或不有化疗)的治疗。对预测生存的预后因素进行单因素和多因素分析。手术范围与局部控制之间有统计学意义的关系(完全切除后的复发率为19.4%，部分切除或活检后复发率为41.2%，p = 0.0001)。纵隔放射剂量(≥50 Gy)对降低复发(p = 0.0001)和远处转移(p = 0.011)有显著作用。局部复发率(30%)和远处转移率(25%)证明恶性胸腺瘤患者推荐更高剂量的纵隔放疗(≥50 Gy)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Genomic Medicine, Biomarkers, and Health Sciences

自引率

0.00%

发文量